Antigenics (NASDAQ: AGEN) 29.4% HIGHER; Announced an oral presentation of updated data from a Phase 1/2 investigator-sponsored trial of the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE